The 2026 update to the European Life Settlement Association’s (ELSA, publisher of Longevity and Mortality Investor) Licensed Provider Matrix suggests a continuing evolution of the secondary life settlement market.
Insurers are favouring funded re as it helps firms manage the market and longevity risks associated with writing bulk purchase annuity (BPA) business by reducing capital charges and therefore making PRT deals more competitive.
Unsurprisingly, given its growth and potential for capital optimisation, UK regulators have been carefully watching the increased use of funded re. In June 2023, the Prudential Regulatory Authority (PRA) sent a “Dear CRO’ letter to heads of risk at UK life insurers.
The letter outlined the regulator’s two main concerns from a sectoral review which it had carried out.
“One of the key risks arising in funded re is that firms recapture sub-optimal portfolios with depressed values and with limited ability to be transformed effectively to the firms’ preferred portfolio,” the PRA letter said.
Related Posts
New Report Suggests Life Settlement Market Poised for Long-Term Expansion
Structural tailwinds provide positive outlook but complexities still need to be managed.
The Structural Decision for Setting Up a Life Settlement Vehicle in Ireland
Two different structuring options provide flexibility for life settlement investors.
Litigation Update: U.S. Bank National Association v. Pacific Life Insurance Company
A recent decision by Judge Thomas J. Lo of the Superior Court of California, Orange…
Is Dementia the Next Big Longevity Event?
For many countries with ageing populations, dementia presents major challenges. Richard Marshall, Senior Director and…
